Comparative study on the efficacy of statin therapy in lowering cholesterol and assessing the risk of metabolic syndrome in patients under statins therapy

Abstract

The objective of the study is to compare and evaluate the efficacy of atorvastatin (group – A) versus rosuvastatin (group – B) on baseline parameters like lipid profile tests and to assess the risk of metabolic syndrome using a Mets calculator. A total of 100 patients were enclosed in the present study who met the inclusion criteria. They were divided into two groups based on their treatment plan Group A includes 24 males and 26 females while Group B includes 23 males and 27 females. The mean differences before treatment for group A and group B are as follows, HDL (31.52±0.35 and 28.34±0.480), LDL (161.4±1.09 and 163.16±0.94), Total cholesterol (252.82±1.09 and 255.56±1.26) and Triglycerides (214.2±0.86 and 215.98±0.62), VLDL (35.98±0.56 and 36.12±0.43). The mean differences after treatment for group A and group B are as follows HDL (39.92±0.46 and 42.04±0.30), LDL (144.96±0.68 and 138.34±0.73), Total cholesterol (181.48±1.98 vs 174.32±2.08), Triglycerides (185.94±1.22 vs 181.74±1.77), VLDL (27.14±0.21 and 24.72±0.27). Group B (P=0.001) exhibited a significantly greater reduction in cholesterol levels as compared to Group A (P = 0.002). The reductions in LDL, VLDL, Total Cholesterol, and Triglycerides along with increased HDL levels were found to be significantly more in the Rosuvastatin group. In this study, we observed that patients on Rosuvastatin exhibited better control over lipid profile when compared to patients who are on Atorvastatin. Since, this study was conducted on a smaller number of patients, to make consecutive remarks about the superiority of either of the treatment regimen; further analysis of clinical trials is required for appropriate selection of the best statin therapy.